At present, no new drugs for cardiomyopathy have appeared in the clinic, and the drug treatment of cardiomyopathy mainly includes angiotensin-converting enzyme inhibitors, β-blockers, cardiotonic drugs of digitalis class and anticoagulants. 1. Angiotensin-converting enzyme inhibitors: such as captopril, benadryl, etc., which have the effect of vasodilating and inhibiting sympathetic nerve excitation, so as to maintain the function of myocardium, delay the progression of heart failure, and reduce the mortality rate. 2. β-blockers: such as metoprolol, bisoprolol, etc., which are mainly used to antagonize the effect of increased sympathetic excitability in the compensatory mechanism, inhibit cardiac remodeling, and reduce mortality. 3. Digitalis-type cardiac drugs: such as digoxin, sildenafil, etc., which can enhance myocardial contractility, inhibit the cardiac conduction system, and directly excite the vagus nerve. 4. Anticoagulants: such as warfarin, heparin, etc. For patients with atrial fibrillation and a history of thromboembolism, long-term oral treatment is required. The treatment of patients with cardiomyopathy should be individualized, and standardized medication is required under the guidance of a specialist.